Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus.
Platelet-bound complement activation products (PC4d) are associated with thrombosis in Systemic Lupus Erythematosus (SLE). This study investigated the effect of PC4d on platelet function, as a mechanistic link to arterial thrombosis. In a cohort of 150 SLE patients, 13 events had occurred within five years of enrollment. Patients with arterial events had higher PC4d levels (13.6 [4.4-24.0] vs. 4.0 [2.5-8.3] net MFI), with PC4d 10 being the optimal cutoff for event detection. The association of arterial events with PC4d remained significant after adjusting for antiphospholipid status, smoking, and prednisone use (p = 0.045). PC4d levels correlated with lower platelet counts (r = -0.26, p = 0.002), larger platelet volumes (r = 0.22, p = 0.009) and increased platelet aggregation: the adenosine diphosphate (ADP) concentration to achieve 50% maximal aggregation (EC50) was lower in patients with PC4d 10 compared with PC4d < 10 (1.6 vs. 3.7, p = 0.038, respectively). These results suggest that PC4d may be a mechanistic marker for vascular disease in SLE.
['Gartshteyn|Yevgeniya|Y|', 'Mor|Adam|A|', 'Shimbo|Daichi|D|', 'Khalili|Leila|L|', 'Kapoor|Teja|T|', 'Geraldino-Pardilla|Laura|L|', 'Alexander|Roberta V|RV|', 'Conklin|John|J|', 'Dervieux|Thierry|T|', 'Askanase|Anca D|AD|']
D000244:Adenosine Diphosphate D001323:Autoantibodies D015551:Autoimmunity D015415:Biomarkers D001792:Blood Platelets D003167:Complement Activation D003181:Complement C4 D004198:Disease Susceptibility D006801:Humans D008180:Lupus Erythematosus, Systemic D015539:Platelet Activation D010974:Platelet Aggregation D010976:Platelet Count D013927:Thrombosis D014652:Vascular Diseases
Platelet Complement split products Systemic lupus erythematosus Thrombosis Antiphospholipid syndrome Autoimmune disease Biomarker Cardiovascular disease Inflammation